Enfoque por país

Policies and Legislation

Enfoque por país/Austria | Posted 24/04/2012

First posted: 24 April 2012 

Austria does not have a coherent generic medicines policy and there is no generic medicines competition within the existing regulatory frameworks [1].

Policies and Legislation

Enfoque por país/Italy | Posted 23/05/2012

First posted: 23 May 2012 

Concerning biosimilars policies in Italy, view the following related articles:

Biosimilars policies in Italy

Biosimilar manufacturers fail to compete in Italy

The term ‘generic medicine’ was first defined in Italian legislation in 1996. A generic medicine has to be marketed under the international non-proprietary name (INN) followed by the name of the company. The definition of ‘generic medicine’ was extended in 2003 to cover all off-patent medicines, including copies (drugs of the same active substance marketed, with their own brand name, often by the originator itself) [1].

Policies and Legislation

Enfoque por país/France | Posted 16/08/2012

First posted: 16 August 2012 

France has a coherent generic medicines policy, however there is no generic medicines competition within the existing regulatory frameworks [1]. Instead, there is competition by discounts to wholesalers and to pharmacists in France [2]. Although discounts of 10.74% are legally allowed in France, actual discounts vary from 20% to 70% of the wholesaler selling price [3].

Policies and Legislation

Enfoque por país/Germany | Posted 10/10/2013

First posted: 10 October 2013 

In Germany, pricing of medicines is officially unregulated even though the authorities influence medicine prices through the reference pricing system (RPS).

Policies and Legislation

Enfoque por país/Poland | Posted 26/11/2013

First posted: 26 November 2013 

Poland does not have a coherent generic medicines policy however there is generic medicines competition within the existing regulatory frameworks [1].

Policies and Legislation

Enfoque por país/The Netherlands | Posted 30/11/2010

In The Netherlands generic pricing is regulated in the same way as originator medicines and has been subject to many policy and legislative changes over the past years, including the Drug Price Act (WGP), the Health Care Market Regulation Act (WMG), Claw-back (De Geus measure), Covenant Years 2004–2007 and Pharmaceutical Care Transaction Agreements.

Policies and Legislation

Enfoque por país/Belgium | Posted 25/05/2011

First posted: 15 September 2011

View the article below to find out ways to increase the utilization of low cost generic atypical antipsychotic drugs in Belgium:

Generic atypical antipsychotic drugs in Belgium